Eric C Deutsch1, Devin Oglesbee2, Nathaniel R Greeley3, David R Lynch1. 1. Department of Pharmacology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA Department of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 2. Department of Laboratory Medicine and Pathology, Department of Molecular Genetics, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, Minnesota, USA. 3. Department of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Abstract
BACKGROUND: Friedreich ataxia (FRDA) is a neurodegenerative disease caused by mutations in the frataxin (FXN) gene, resulting in reduced expression of the mitochondrial protein frataxin. Improved understanding of the pathophysiology of the disease has led to a growing need for informative biomarkers to assess disease progression and response to therapeutic intervention. OBJECTIVE: To evaluate the performance of frataxin measurements as a diagnostic tool using two different immunoassays. METHODS: Clinical and demographic information was provided through an ongoing longitudinal natural history study on FRDA. Frataxin protein levels from multiple cell types in controls, carriers and FRDA patients were measured and compared using a lateral flow immunoassay and a Luminex xMAP-based immunoassay. Receiver operating characteristic curve analyses were then performed to evaluate the sensitivity, specificity, and positive and negative predictive values for each immunoassay. RESULTS: For whole blood and buccal cells, analysing FRDA patients and carriers together in a cohort resulted in higher sensitivities and positive predictive values compared with analyzing controls and carriers together, with similar results between each tissue type. We then compared the usefulness of a lateral flow immunoassay with a multianalyte Luminex xMAP-based immunoassay, and showed that both assays demonstrate high positive predictive values with low rates of false negatives and false positives. CONCLUSIONS: Frataxin measurements from peripheral tissues can be used to identify FRDA patients and carriers. While multiple cell types and assays may be useful for diagnostic purposes, each assay and cell type used has its advantages and disadvantages depending on study design and scope. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:Friedreich ataxia (FRDA) is a neurodegenerative disease caused by mutations in the frataxin (FXN) gene, resulting in reduced expression of the mitochondrial protein frataxin. Improved understanding of the pathophysiology of the disease has led to a growing need for informative biomarkers to assess disease progression and response to therapeutic intervention. OBJECTIVE: To evaluate the performance of frataxin measurements as a diagnostic tool using two different immunoassays. METHODS: Clinical and demographic information was provided through an ongoing longitudinal natural history study on FRDA. Frataxin protein levels from multiple cell types in controls, carriers and FRDApatients were measured and compared using a lateral flow immunoassay and a Luminex xMAP-based immunoassay. Receiver operating characteristic curve analyses were then performed to evaluate the sensitivity, specificity, and positive and negative predictive values for each immunoassay. RESULTS: For whole blood and buccal cells, analysing FRDApatients and carriers together in a cohort resulted in higher sensitivities and positive predictive values compared with analyzing controls and carriers together, with similar results between each tissue type. We then compared the usefulness of a lateral flow immunoassay with a multianalyte Luminex xMAP-based immunoassay, and showed that both assays demonstrate high positive predictive values with low rates of false negatives and false positives. CONCLUSIONS:Frataxin measurements from peripheral tissues can be used to identify FRDApatients and carriers. While multiple cell types and assays may be useful for diagnostic purposes, each assay and cell type used has its advantages and disadvantages depending on study design and scope. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
MITOCHONDRIAL DISORDERS; MOVEMENT DISORDERS; PAEDIATRIC
Authors: Andrew J Worth; Sankha S Basu; Eric C Deutsch; Wei-Ting Hwang; Nathaniel W Snyder; David R Lynch; Ian A Blair Journal: Bioanalysis Date: 2015 Impact factor: 2.681
Authors: Qingqing Wang; Laurent Laboureur; Liwei Weng; Nicolas M Eskenazi; Lauren A Hauser; Clementina Mesaros; David R Lynch; Ian A Blair Journal: Front Neurosci Date: 2022-04-28 Impact factor: 5.152
Authors: Elisia Clark; Joseph Johnson; Yi Na Dong; Elizabeth Mercado-Ayon; Nathan Warren; Mattieu Zhai; Emily McMillan; Amy Salovin; Hong Lin; David R Lynch Journal: Neuronal Signal Date: 2018-11-02
Authors: David R Lynch; Lauren Hauser; Ashley McCormick; McKenzie Wells; Yi Na Dong; Shana McCormack; Kim Schadt; Susan Perlman; Sub H Subramony; Katherine D Mathews; Alicia Brocht; Julie Ball; Renee Perdok; Amy Grahn; Tom Vescio; Jeffrey W Sherman; Jennifer M Farmer Journal: Ann Clin Transl Neurol Date: 2019-02-27 Impact factor: 4.511
Authors: Joseph F Nabhan; Renea L Gooch; Eugene L Piatnitski Chekler; Betsy Pierce; Christine E Bulawa Journal: Sci Rep Date: 2015-12-16 Impact factor: 4.379